Does Pendulum’s GLP-1 Probiotic Work? The Evidence, Bottle by Bottle

No molecule has had a decade like GLP-1. The hormone behind Ozempic and its siblings has pulled everything in wellness into its orbit — and no company has ridden that gravity more skilfully than Pendulum, the Sequoia-backed probiotic maker whose GLP-1 Probiotic launched in March 2024 with the most seductive pitch in the supplement aisle: help your body make more of the famous hormone naturally. Pendulum is, by supplement-industry standards, a genuinely serious science company. Which is exactly why its shelf deserves a serious reading — bottle by bottle, study by study. What that reading turns up is a fact almost nobody buying the flagship knows: Pendulum has run one human trial, and it is not on this product.

The companyWhat is Pendulum?

Pendulum Therapeutics was co-founded by CEO Colleen Cutcliffe, a biochemistry PhD, and earned its scientific reputation on a real achievement: it was the first company to commercialize Akkermansia muciniphila, a strictly anaerobic gut bacterium — oxygen kills it — that most of the industry considered impossible to culture at scale. That is hard microbiology, done properly, and it is why Pendulum sits in a different class from the commodity-probiotic crowd. The commercial engine matches the science pedigree: Sequoia money, a nationwide grocery rollout, a steady presence on the biggest wellness podcasts, and — since February 2023 — Halle Berry as investor, equity owner and Chief Communications Officer.

The one human trialWhat has Pendulum actually tested in people?

One formulation, once. In a 2020 trial in BMJ Open Diabetes Research & Care — run by the company, and labelled a proof-of-concept by its own authors — 76 adults with type 2 diabetes at six US sites took one of two candidate formulations or placebo for 12 weeks, double-blind. The five-strain formulation called WBF-011, now sold as Glucose Control, improved the primary outcome: post-meal glucose area-under-the-curve fell 36.1 mg/dL over 180 minutes versus placebo, with A1C down 0.6 points. Two details belong in any honest retelling. The p-value on that primary outcome was 0.0500 — landing exactly on the conventional line for statistical significance, not comfortably inside it. And the trial’s other candidate formulation, WBF-010, did not significantly improve anything — a useful reminder that in microbiome science, the specific recipe is the product, not the ingredient list.

None of that is a knock on running the trial. A randomized, placebo-controlled, multicenter study is more human evidence than the overwhelming majority of the probiotic industry has ever produced, and Pendulum deserves the credit it claims for it. The question is what happens when one trial’s credibility has to stretch across a whole shelf.

The mouse and the proteinWhere does the GLP-1 claim actually come from?

From a genuinely elegant piece of science — in mice. In a 2021 Nature Microbiology paper, Korean researchers identified an 84-kilodalton protein secreted by Akkermansia muciniphila, named P9, that induces GLP-1 secretion from gut cells, working through a receptor pathway they mapped in detail. Mice on a high-fat diet given the bacterium or the purified protein secreted more GLP-1, ran warmer brown fat, and handled glucose better. It is the kind of mechanism paper that launches a thousand headlines, and it earned them. It is also, to date, where the direct evidence stops: no published human trial has shown that swallowing these strains raises GLP-1 in a person.

The label, read closelyWhat does the GLP-1 Probiotic actually promise?

Read Pendulum’s own product page carefully — it rewards it. The claim is that the three-strain formula is “formulated to naturally support your body’s own GLP-1 signaling pathways.” The asterisk beneath it says, verbatim: “Based on preclinical studies. Not intended for weight loss.” The page states plainly that the product “does not contain GLP-1 and is not a GLP-1 agonist drug.” And its headline efficacy numbers rest on “a consumer survey of 274 people taking GLP-1 Probiotic for six weeks” — a survey, not a trial. Note also what is in the bottle: three strains, sharing three of the trialed formulation’s five. The 2020 trial tested a different recipe — and this is the company whose own trial showed that the recipe is what matters.

Here is the fair reading: every disclaimer above was printed by Pendulum itself, and that candour is genuinely to its credit — the company says plainly what the product is not. But candour in the footnotes coexists with a halo in the branding, and the halo is doing the selling. The word GLP-1 on the label borrows its glow from drugs with mountains of human outcome data; the asterisk hands the borrowing back. The customer connecting those two facts is doing work the marketing does not do for them.

The momentWhy this product, why now?

Because the appetite for a “natural Ozempic” may be the single strongest current in wellness, fed by people who cannot access the drugs, cannot afford them, cannot tolerate them, or simply mistrust them. A probiotic that whispers the magic acronym — at prices running $69 to $139 a month across the Pendulum line — meets that current perfectly. This is not deception; it is positioning, executed superbly by a company with real science underneath it. It is also precisely the situation in which reading what the studies measured, rather than what the shelf implies, earns its keep.

The bottom lineWhat would settle it?

A published human trial of the GLP-1 Probiotic itself, measuring GLP-1 levels or appetite and weight outcomes against placebo. Pendulum is one of the few companies in the category with the demonstrated ability to run one. Until it does, the honest summary reads: a company-funded proof-of-concept trial supports Glucose Control’s glucose effects in type 2 diabetes, at the edge of statistical significance; the GLP-1 flagship rests on a mouse protein and a customer survey; and the company itself tells you, in small print, not to expect weight loss. Anyone with diabetes considering any product that moves blood glucose should involve their clinician first — especially alongside glucose-lowering medication. For how this species earned its reputation in the first place, see our reporting on what gut tests can and cannot measure and why strain-level evidence is the only kind that counts. This audit is part of Gut Check, our running evidence review of the gut-health industry. It is educational and is not medical advice.